Rinzimetostat (TFA)

Rinzimetostat (ORIC-944) TFA is the TFA salt form of ORIC (HY-158102) . Rinzimetostat TFA is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2) . Rinzimetostat TFA is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer[1][2].

Product Specifications

Product Name Alternative

ORIC-944 (TFA)

UNSPSC

12352005

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/oric-944-tfa.html

Purity

98.87

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC1=C(C=CC(CN(C)C)=C1)C2=CN=C(N3C=C(N=C23)C#N)NCC4=C(C=CC5=C4CCO5)F.O=C(C(F)(F)F)O

Molecular Formula

C28H26F4N6O3

Molecular Weight

570.54

References & Citations

[1]Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84 (6_Supplement) : 6586-6586.|[2]ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones